Israeli AI disease models co CytoReason raises $80m
InvestmentPartnersExpand
Momentum for Poolbeg and CytoReason's AI collaboration - PharmaTimes
Partners
Sanofi extends cooperation with Israel's CytoReason for bowel disease drug discovery
Partners
CytoReason raises $20 million from Pfizer for AI drug discovery and development platform | CTech
PartnersInvestment
CytoReason Expands Its Reach in Asia, Forging Commercial Alliance with Helixrus to Leverage Machine Learning in Drug Development for Korean Drugmakers
Partners
Pfizer extends cooperation deal with Israeli AI drug development firm CytoReason
Partners
סייטוריזן פיתחה תוכנת AI המנבאת הצלחה של ניסויים קליניים - Techtime - חדשות אלקטרוניקה והייטק
Investment
Merck KGaA taps CytoReason's machine learning platform to profile immuno-oncology drug
CytoReason, Summit tap into AI on Japanese drug development effort
Partners
CytoReason enters Japanese market with SPI partnership
Partners
CytoReason Collaborates with Sanofi, Using its AI Technology to Gain Better Understanding of Disease Mechanisms
Partners
CytoReason Announces Collaboration with Ferring to Identify Novel Therapeutic Targets in Inflammatory Bowel Disease Using AI Technology
Partners
The secret Israeli sauce in Pfizer's new drug mix - Sponsored Content The Times of Israel
Partners
AI-Powered Drug Development in a Post-COVID World
When can computer models replace animal trials? - Drug Discovery and Development
Customers
New Startup Helps Pfizer Create More Effective, Targeted Drugs For Patients - The Tennessee Tribune
Partners
https://www.jpost.com/opinion/hillels-tech-corner-cytoreason-where-ai-meets-drug-development-631184
PartnersCustomers
סייטוריזון בנבחרת הסטארטאפים 2020 של TheMarker
Investment
Ground Breaking New Methodology Published in Nature Medicine Uncovers the Missing Numbers to the Only Clock That Really Matters in the Body - Your Immune Age
Investment
CytoReason teams with Pfizer on drug discovery
Partners